Day: January 4, 2021

Oslo, 4 January 2021This announcement is submitted on behalf of certain primary insiders in Thin Film Electronics ASA (“Thinfilm” or the “Company”).On 31 December 2020, Kevin Barber, CEO of Thinfilm, submitted written instructions to exercise 909,090 Warrants A. If and when subsequently approved by the board of directors, each Warrant A will be converted into one new share in the Company, totaling 909,090 new shares, upon payment of the exercise price of 0.11 NOK per share. Following approval of the warrant exercise and subsequent issuance of shares, Kevin Barber would hold a total of 1,818,180 shares, 909,090 Warrants B, and 32,331,560 incentive subscription rights (SRs) in Thinfilm.On 31 December 2020, chair of the board Morten Opstad and close associates of Morten Opstad submitted written instructions to exercise...

Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.      ·ODDO BHF Digital ForumDate: January 7-11, 2021      ·SternIR Virtual Corporate Access EventDate: January 11-14, 2021Presentation: A pre-recorded presentation will be available for on-demand viewing in the Investors section of the Innate Pharma website, www.innate-pharma.com, beginning Monday, January 11, 2021.About Innate Pharma:Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to...

January 4, 2021Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 a.m. ET.A live webcast of the presentation will be available on the Company’s website at www.argenx.com. A replay of the webcast will be available for 90 days following the presentation.About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology...

Marseille, 04 janv. 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris : IPH – ISIN: FR0010331421; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que des membres de son équipe de direction seront présents aux conférences investisseurs virtuelles suivantes :ODDO BHF Digital ForumDate: du 7 au 11 janvier 2021SternIR Virtual Corporate Access EventDate: du 11 au 14 janvier 2021Présentation: Une présentation préenregistrée sera disponible dans la section Investisseurs du site web d’Innate Pharma, www.innate-pharma.com, à partir du lundi 11 janvier 2021.À propos d’Innate Pharma :       Innate Pharma S.A. est une société de biotechnologies au stade clinique, spécialisée en immuno-oncologie et dédiée à l’amélioration du traitement des cancers grâce à des anticorps thérapeutiques innovants exploitant le système immunitaire.Le...

MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.ODDO BHF Digital ForumDate: January 7-11, 2021SternIR Virtual Corporate Access EventDate: January 11-14, 2021Presentation: A pre-recorded presentation will be available for on-demand viewing in the Investors section of the Innate Pharma website, www.innate-pharma.com, beginning Monday, January 11, 2021.About Innate Pharma:Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight...

 Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of David Renas as Chief Financial Officer (CFO) and member of the company’s Executive Committee, effective today. He will be based in the U.S.“David has demonstrated a track record of leadership and we are delighted to welcome him onto the executive team,” said Brian O’Callaghan, Chief Executive Officer of ObsEva. “I’m confident he will play a key role in further strengthening our relationships with investors and potential partners as we prepare to file a new drug application (NDA) in the U.S. in the first half of 2021 for Yselty, for the treatment of heavy menstrual bleeding and pain...

Start of operations at the biomass power plant of Cacao, in French GuianaVoltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces that the Cacao biomass plant in French Guiana produced its first kilowatt-hours on December 17, 2020. Thanks to an investment of around €75 million, this biomass power plant produces decarbonated electricity sold at a price below the cost of Guiana’s thermal power plants, while contributing to making this Territory autonomous in terms of energy.“Renewable energies, which already account for 50% of the energy mix of French Guiana, are a key solution to meet the growing demand for energy by local households. In this respect, biomass, which enables Voltalia to supply electricity continuously, is particularly well suited to the Territory, where there is...

Début de production à la centrale biomasse de Cacao en Guyane françaiseVoltalia (Euronext Paris, code ISIN : FR0011995588), acteur international des énergies renouvelables, annonce que la centrale biomasse de Cacao en Guyane française a produit ses premiers kilowattheures le 17 décembre 2020. Grâce à un investissement d’environ 75 millions d’euros, cette centrale biomasse produit une électricité décarbonée vendue à un prix inférieur au coût des centrales thermiques guyanaises, tout en contribuant à l’autonomie énergétique du Territoire.« Les énergies renouvelables, qui représentent déjà 50 % du mix énergétique de la Guyane, sont une solution clé pour répondre à la demande croissante en énergie des foyers guyanais. A ce titre, la biomasse, qui permet à Voltalia de fournir de l’électricité en continu, est particulièrement adaptée au Territoire...

-eAdvisor.app is offering financial planning services to financial advisors.-Social Security planning, and Canada Pension Plan planning.-Planning for multiple tax strategies and spending strategies to help client’s money last and make leaving a legacy possible.-Planner focuses on clearly showing clients the effects of multiple scenarios and possibilities that could affect their financial state. eAdvisor.app is a Financial Planning Software, focused on providing advisors with the ability to quickly and easily show clients a multitude of scenarios on simulated (Monte Carlo) and real historical data. Tax Strategies and Spending Rules area also available to show clients the effects of how, when, and from where they withdraw their money. Tax Strategies allow clients to see the effects of withdrawing from taxable vs. non-taxable accounts, and...